Introduction
============

Fetal growth restriction (FGR), where the fetus fails to reach its genetic growth potential, is a prevalent clinical problem affecting 3--5% of pregnancies ([@B44]; [@B9]). FGR is defined as an estimated fetal weight of less than the 3rd centile or a contribution of two of the following factors: EFW less than the 10th centile, a 2 quartile drop in growth centiles, or abnormal uterine artery Doppler pulsatility index greater than the 95th centile, ([@B32]). FGR is associated with both short and long-term adverse outcomes, increasing the risk of perinatal morbidity and mortality ([@B12]; [@B50]; [@B14]; [@B19]), as well as the development of cardio-metabolic disease in later life ([@B10]). Despite the severe consequences of FGR, there remain limited interventions available to clinicians to either improve pregnancy outcome (e.g., low dose aspirin and steroid administration) or to mitigate the adverse outcomes for FGR neonates ([@B3]; [@B55]). There is a clear need for the development of safe and effective interventions to improve pregnancy outcomes.

The underlying etiology of FGR is complex but placental dysfunction underlies most idiopathic cases ([@B18]). This may arise from inadequate spiral artery remodeling ([@B34]), an adaptation of early pregnancy which lowers vascular resistance and facilitates maternal blood flow to the placenta ([@B17]; [@B18]). Failed artery remodeling leads to placental hypoxia/oxidative stress and abnormal development of the feto-placental blood vessels ([@B16]). Severe early onset FGR (before 34 weeks gestation), is associated with abnormal umbilical artery and uterine artery flow-velocity as determined clinically by Doppler waveform analysis ([@B31]). Abnormal vascular development and regulation of vascular tone both contribute to inadequate blood flow from mother to placenta, and between placenta and fetus, which compromises fetal growth and development ([@B35]).

The endothelial nitric oxide synthase knock out (eNOS^−/−^) mouse provides a well-characterized model of FGR, with phenotypic similarities to human FGR where; fetuses are ∼10% smaller compared with their wild type (WT) counterparts near term ([@B39]; [@B36]), and knockout animals demonstrate impaired uterine artery reactivity ([@B39]), reduced uterine and umbilical blood flow ([@B37]) and increased systolic blood pressure ([@B54]). Additionally, in common with human FGR, there is evidence of increased reactive oxygen species (ROS) generation in the placentas of eNOS^−/−^ mice ([@B39]) compared to WT. Whilst in pregnancy there is an increase in ROS production due to the high metabolic rate of the placenta ([@B48]), excessive ROS production or a deficit in cellular anti-oxidant mechanisms can result in oxidative damage within the placenta and its vasculature ([@B61]); this oxidative damage is thought to contribute to many pregnancy complications including FGR ([@B15]).

Pomegranate juice (PJ) consumption has been demonstrated to have a number of beneficial cardiovascular effects ([@B8]) and is often advocated as a well tolerated dietary supplement to improve vascular health ([@B11]). These beneficial actions of PJ are thought to be due to the high concentration of bioactive polyphenol compounds including: anthocyanins, tannins (particularly the ellagitannin, punicalagin), phenols and flavonoids, found in pomegranate as well as other fruits ([@B56]; [@B43]). Indeed isolated phenolic compounds and extracts of fruits, including pomegranate, have been show to exhibit important anti-oxidant actions, and to enhance isolated vessel reactivity in rats ([@B30]; [@B2]; [@B27]). Furthermore pomegranate has the ability to reduce systolic blood pressure in both a rat model of hypertension ([@B27]) and in hypertensive patients ([@B6]). In pregnancy, PJ supplementation has been shown to limit oxidative stress induced injury, both *in vitro* (reducing oxidative stress and apoptosis in placental trophoblast cells) and *in vivo* (following maternal consumption) in the placentas of pre-eclamptic patients ([@B23], [@B21]).

Given the promising effects of pomegranate polyphenols on vascular function in non-pregnant animal models and humans, the ability of PJ to promote utero- and fetoplacental vascular function during fetal development and potentially improve fetal growth in FGR is worthy of investigation. Furthermore, despite the beneficial effects of pomegranate consumptions on adult health, little is known about the effect(s) of high polyphenol consumption on fetal development ([@B40]) and it is likely that the developing fetus may be particularly susceptible to perturbations in redox balance ([@B57]).

Here, we tested the hypothesis that maternal PJ supplementation would improve uterine and umbilical artery function and increase fetal growth in the eNOS^−/−^ model of FGR, without any gross perturbations to fetal development.

Materials and Methods {#s1}
=====================

Mice and Ethical Approval
-------------------------

Animal care and experimental procedures were performed in accordance with the UK Animals (Scientific Procedures) Act 1986 under Home Office licenses PPL 40/3385 and PPL 70/8504. The Local Ethical Review Process of the University of Manchester approved all protocols. eNOS^−/−^ mice were obtained from Jackson Laboratories (strainB6.129P2-Nos3tm1Unc/J). C57/BL6J mice, the background strain, were used as the WT control. Mice were mated and the presence of a copulation plug was denoted as embryonic day (E) 0.5 of pregnancy. All female mice were 10--16 weeks old at time of mating; male mice were 12--26 weeks old. At E12.5 (term E19.5) mice were randomly assigned to receive either PJ administered via the drinking water or drinking water alone for the remainder of pregnancy. E12.5 was chosen as the time-point of intervention to coincide with a gestational age analogous to human second trimester when FGR could reasonably be diagnosed and therapeutic intervention initiated. Animals had free access to food (BK001 diet, Special Dietary Services, United Kingdom) and water (Hydropac, Lab products Inc, Seaford, DE, United States) or PJ diluted in water (see specific dose information below), and were maintained on a 12:12-h light-dark cycle at 21--23°C in individually ventilated cages. All animals were sacrificed by cervical dislocation at E18.5 and the placentas, fetuses, uterine and umbilical arteries harvested.

Pomegranate Juice Treatment
---------------------------

Pomegranate juice treated dams received a PJ solution of commercially available POM wonderful juice \[Los Angeles, CA, United States ([@B43])\] diluted in drinking water to a final concentration of 3% (v/v). This provides an expected dose of 0.31 μmol polyphenols/day or 0.55 mg/kg, based on an expected fluid consumption of 5 ml per mouse per day, determined in previous studies in our group, ([@B28]). This dose was in line with doses previously shown to have biological activity in animal models ([@B7]) and was further chosen with the aim of providing animals with an equivalent dose to a human adult drinking a 240 ml (8oz) glass of juice daily, equivalent to many clinical trial doses ([@B43]; [@B23]). Drinking bottles contained 100 ml of PJ solution or water and were changed each morning (8am -- 10am) and drinking volumes calculated based on fluid remaining. Fluid intake (E12.5 -- E18.5) was comparable for all treatments and maternal weight gain was not different between genotype or treatment groups (WT = 10.13 g ± 7.6, eNOS^−/−^ = 8.57 g ± 1.05, WT+PJ = 8.9 g ± 3.37, eNOS^−/−^ +PJ = 8.5 g ± 1.46). Median baseline weights at the commencement of treatment was 27 grams, (range 23.5--29.5 g).

Fetal and Placental Measurements
--------------------------------

Fetal and placental wet weights were measured at E18.5 and growth curves constructed as previously described ([@B29]). Biometric measurements (crown-rump length, abdominal circumference and head circumference) were made as previously described ([@B29]).

Wire Myography
--------------

Main loop uterine arteries (UtAs) and umbilical arteries (UmbAs) were dissected from eNOS^−/−^ and WT dams and fetuses at E18.5 and mounted onto a wire myograph (Danish Myo Technologies 610M; DMT, Aarhus, Denmark) and bathed in physiological salt solution (PSS) as described previously ([@B38]). Normalization procedures were performed as described in detail previously ([@B60]), whereby artery diameters were normalized to 0.9L~13.3~ for UtAs and 0.9L~5.1~ for UmbAs (diameter of vessel at which luminal pressures were 13.3 and 5.1 kPa respectively); calculated vessel diameters were recorded. Vessels were allowed to equilibrate for 20 min post normalization before the commencement of vasoactive studies. Maximal smooth muscle contraction was measured by exposing vessels to KPSS solution (120 mM KCl substituted for NaCl). Drug-induced contraction was measured using incremental doses of phenylephrine (PE;10^−9^ to 10^−5^M) in uterine arteries and thromboxane mimetic U46619 (10^−9^ -- 2 × 10^−6^M) in umbilical arteries at 2 min intervals. Endothelium-dependent relaxation to acetylcholine (Ach; 10^−9^ to 10^−5^M) and endothelium-independent relaxation to sodium nitro-prusside (SNP; 10^−9^ to 10^−5^M) was assessed in UtAs and UmbAs pre-contracted with 10^−5^M PE and an EC~80~ of U46619 (as calculated from the U46619 dose response curve), respectively.

Data Analysis
-------------

For myography analysis, average responses from 2 to 4 vessels (UmbA) or 2--4 vessel segments (UtA) per dam were calculated from *N* = 14--20 dams (UtA) and *N* = 11--13 dams (UmbA), and were compared between genotype and treatment groups. Artery contraction is expressed as active effective pressure (kPa) calculated as follows:
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Artery relaxation is presented as active effective pressure in response to the vasodilator expressed as a % of the maximum pre-constriction achieved with PE or U46619 (later denoted as 100%). Data are presented as mean ± SEM with *n* = number of vessels, *N* = number of animals. Statistical analysis is via two-way ANOVA, with Sidak's *post hoc* test where appropriate. EC~50~ concentrations for dose-response curves were calculated for each vessel individually by applying a sigmoidal dose response curve fit to the data. Differences in vessel diameter, basal tone, KPSS response and EC50s were assessed by two-way ANOVA or Kruskal--Wallis test and data are presented as individual data points with median. Sample size calculations were based on a 5% significance level, with 80% statistical power. For an approximate 15% improvement in vascular function (based on increase in maximal Ach-induced relaxation), with a standard deviation of 18%, effect size estimate is 0.850. A minimum sample size of 11 animals per group is therefore required.

Litter means for placental weight, fetal weight were calculated and the data are presented as scatterplots with median of *N* = 14--20 l. Fetal weight distribution curves are also presented. Statistical analysis was via two-way ANOVA or Kruskal--Wallis test as appropriate.

Results
=======

Effect of PJ Supplementation on Uterine Artery Reactivity
---------------------------------------------------------

UtAs of eNOS^−/−^ mice were ∼15--20% smaller in diameter than arteries of WT mice irrespective of treatment (WT = 254 μm ± 7, eNOS^−/−^ = 212 μm ± 9, WT + PJ = 237 μm ± 7, eNOS^−/−^ +PJ = 203 μm ± 9, two-way ANOVA effect of genotype, *P* \< 0.0001). Basal tone of normalized vessels (i.e., tone at passive relaxation), expressed as mmHg, was not affected by genotype but was increased in vessels from both WT and eNOS^−/−^ mice that had been consuming PJ (**Figure [1A](#F1){ref-type="fig"}**, two-way ANOVA significant effect of treatment). The initial contraction to KPSS was lower in eNOS^−/−^ mice (vs. WT), but this effect was not evident in vessels from PJ supplemented eNOS^−/−^ mice. PJ supplementation had no effect on KPSS-induced contraction in arteries from WT mice (**Figure [1B](#F1){ref-type="fig"}**). UtA contraction in response to PE was similar in eNOS^−/−^ and WT mice, but in eNOS^−/−^ mice, PJ supplementation significantly increased contraction to PE vs. water controls (**Figures [1C,D](#F1){ref-type="fig"}**).

![Contraction of uterine arteries. Pomegranate juice significantly increased uterine artery (UtA) basal tone vs. untreated vessels irrespective of genotype **(A)**. The initial constriction to KPSS **(B)** was lower in eNOS^−/−^ mice compared to WT. Data are mean ± SEM of 2--4 vessels/animal *N* = 14--20 dams/group, lines represent median. ^ϕ^*P* \< 0.05, significant effect of treatment vs. genotype matched control, one-way ANOVA. ^∗^*P* \< 0.05 significant effect of genotype. PJ supplementation did not affect uterine artery contraction to phenylephrine in WT mice **(C)** but significantly enhanced contraction in eNOS^−/−^ mice **(D)**. Data are mean ± SEM ^ϕ^*P* \< 0.05, significant effect of treatment, two-way ANOVA.](fphys-09-01145-g001){#F1}

Consistent with the eNOS^−/−^ phenotype reported by us ([@B39]) and others ([@B37], [@B36]), relaxation to Ach was significantly attenuated and relaxation to SNP was potentiated in eNOS^−/−^ compared with WT mice, (**Figures [2A,B](#F2){ref-type="fig"}**). PJ supplementation reduced agonist induced UtA relaxation to both Ach and SNP in WT but not eNOS^−/−^ mice. This reduced relaxation response was paralleled by a reduced sensitivity to agonists with a significant increase in EC~50~ (**Figures [2C,D](#F2){ref-type="fig"}**) in WT mice. There was no effect of PJ supplementation on EC~50~ for Ach and SNP-induced relaxation in eNOS^−/−^ mice (data not shown).

![Relaxation of uterine arteries. Relaxation of UtAs from WT and eNOS^−/−^ mice in response to Acetlycholine (Ach) **(A)** and Sodium Nitroprusside (SNP) **(B)**. Relaxation in response to Ach was significantly reduced, whereas SNP induced relaxation was significantly enhanced in eNOS^−/−^ mice compared to WT irrespective of treatment. Pomegranate juice supplementation significantly reduced the relaxation responses to both Ach and SNP in WT but not eNOS^−/−^ animals. Data are mean ± SEM of averages of 2--4 vessels/animal *N* = 14--20 dams/group. EC~50~ doses of both Ach **(C)** and SNP **(D)** were higher in WT animals supplemented with PJ representing a decreased sensitivity of UTAs following supplementation. *n* = 22--31 vessels, line = median. ^∗^*P* \< O.05, ^∗∗∗^*P* \< 0.001, significant effect of genotype. ^ϕ^*P* \< 0.05, significant effect of treatment.](fphys-09-01145-g002){#F2}

Effect of PJ Supplementation on Umbilical Artery Reactivity
-----------------------------------------------------------

As with UtAs, UmbAs from eNOS^−/−^ mice were smaller than WT (WT = 482 μm ± 12, eNOS^−/−^ = 445 μm ± 12, two-way ANOVA effect of genotype, *p* = 0.0112) and there was no effect of PJ supplementation on vessel diameter. There was no effect of genotype or treatment on basal tone or KPSS contraction (data not shown).

UmbA maximal contraction to U46619 was not affected by PJ supplementation in either WT or eNOS^−/−^ mice (**Figures [3A,B](#F3){ref-type="fig"}**); however the sensitivity to U46619 was increased following PJ supplementation, with a significant reduction in EC~50~ in vessels from WT animals (**Figure [3C](#F3){ref-type="fig"}**).

![Umbilical artery contraction. PJ supplementation did not affect the maximal UmbA contraction in response to U46619 in either WT **(A)** or eNOS^−/−^ **(B)** mice, *N* = 11--13 dams, *n* = 28--36 vessels. The EC~50~ dose **(C)** was significantly lower in vessels from WT mice supplemented with PJ. ^ϕ^*P* \< 0.05, significant effect of treatment in WT vessels, two-way ANOVA.](fphys-09-01145-g003){#F3}

As previously reported UmbAs contracted in response to increasing concentrations of Ach ([@B38]), an effect that was significantly increased following PJ supplementation in both WT and eNOS^−/−^ mice (**Figures [4A,B](#F4){ref-type="fig"}**). In addition, relaxation to SNP was potentiated by PJ treatment in UmbAs of both WT and eNOS^−/−^ mice (**Figures [4C,D](#F4){ref-type="fig"}**).

![Effect of ACh and SNP on umbilical arteries. Ach induced contraction of UmbAs from both WT **(A)** and eNOS^−/−^**(B)** mice. Contraction was increased following PJ supplementation in both genotypes. SNP induced relaxation of UmbAs in WT **(C)** and eNOS^−/−^**(D)** mice and relaxation was potentiated by PJ supplementation in both genotypes. *N* = 11--13 dams, *n* = 28--36 vessels. ^ϕ^*P* \< 0.05, ^ϕϕ^*P* \< 0.01, ^ϕϕϕ^*P* \< 0.001 significant effect of treatment two-way ANOVA.](fphys-09-01145-g004){#F4}

Effect of PJ Supplementation on Fetal Characteristics
-----------------------------------------------------

Litter size of both WT and eNOS^−/−^ mice was significantly reduced by PJ treatment (**Figure [5A](#F5){ref-type="fig"}**). However there was no corresponding effect on number of fetal resorptions (data not shown). eNOS^−/−^ fetuses were smaller than their WT counterparts (**Figures [5B,D](#F5){ref-type="fig"}**); neither mean fetal weight not fetal weight distribution was altered by PJ treatment in either genotype irrespective of fetal sex (data not shown). Placental weight was comparable between all groups (**Figure [5C](#F5){ref-type="fig"}**) resulting in a significantly decreased fetal:placental weight ratio in eNOS^−/−^ litters (WT = 14.02 ± 0.22, eNOS^−/−^ = 12.41 ± 0.23, *p* \< 0.001). Consistent with their growth restricted phenotype, eNOS^−/−^ fetuses were smaller than their WT counterparts, with the largest differences seen in abdominal circumference suggesting a degree of head sparing (**Table [1](#T1){ref-type="table"}**). Despite the lack of an effect of PJ on fetal weight, biometric measurements were affected by PJ supplementation (**Table [1](#T1){ref-type="table"}**). These effects tended to be detrimental with significant reductions in both abdominal circumference and head circumference in WT and eNOS^−/−^ mice treated with PJ.

![Litter size, fetal and placental weight. Litter size **(A)** was significantly reduced by PJ treatment, in both eNOS^−/−^ and WT mice (^ϕ^*P* \< 0.05, two-way ANOVA). Fetal weight was lower in eNOS^−/−^ mice irrespective of treatment **(B)**, ^∗∗∗^*p* \< 0.001, two-way ANOVA. There was no effect of genotype or treatment on placental weight **(C)**. *N* = 14--20 l. Fetal weight distribution curves **(D)** showed no differences in weight distribution following treatment, *n* = 78--143 pups from *N* = 14--20 l.](fphys-09-01145-g005){#F5}

###### 

Biometric measurements.

  Biometric measurements         WT            WT + PJ          eNOS^−/−^         eNOS^−/−^ + PJ
  ------------------------------ ------------- ---------------- ----------------- ------------------
  Crown-rump length (mm)         29 (27--31)   28 (28--31)      28 (26--29)^∗^    28 (27--29)^∗^
  Head circumference (mm)        29 (26--29)   27 (27--28)^ϕ^   28 (25--29)^∗^    26 (24--29)^∗ϕ^
  Abdominal circumference (mm)   27 (24--29)   27 (25--27)^ϕ^   26 (24--28)^∗∗^   25 (23--27)^∗∗ϕ^

Measurements of crown-rump length, head circumference and abdominal circumference median (range), N = 14--20 l, n = 56--80 fetuses. eNOS

−/−

fetus' were smaller by all measures compared to WT (two-way ANOVA:

∗

p \< O.05,

∗∗

p \< 0.01 vs. WT control). PJ supplementation significantly reduced head circumference and abdominal circumference irrespective of genotype (two-way ANOVA,

ϕ

P \< 0.05 vs. genotype matched water drinking control).

Discussion
==========

Contrary to our hypothesis, PJ supplementation from E12.5-E18.5 of pregnancy did not improve fetal growth in eNOS^−/−^ mice. However it did have pronounced effects on vascular function of both UtAs and UmbAs with interesting differential effects in the different vascular beds and in different genotypes. In WT animals, PJ supplementation decreased sensitivity to agonist-induced relaxation (Ach and SNP) in UtAs whereas in UmbAs relaxation responses to SNP were increased, with PJ also increasing sensitivity of UmbAs to contraction in response to both U46619 and Ach. In eNOS^−/−^ animals, PJ supplementation had the same effects on UmbAs (enhancing contractile responses and increasing relaxation to SNP) but in UtAs contraction to PE was enhanced with no observable effect on relaxation responses. These findings, along with the significant reduction in litter size, and the reduction in fetal head and abdominal circumference irrespective of genotype, do not support maternal PJ supplementation as an effective therapy to improve fetal growth in FGR.

Differential Effects of Pomegranate Juice Supplementation on Vasculature in Different Genotypes
-----------------------------------------------------------------------------------------------

In eNOS^−/−^ mice, UtA and UmbA diameters were smaller but basal tone was comparable. Vessel reactivity of UtAs in untreated eNOS^−/−^ mice was significantly decreased, with reduced artery contraction to depolarizing concentrations of potassium and blunted endothelial dependent relaxation to Ach, as demonstrated previously ([@B20]; [@B39]). Relaxation to the endothelial independent agonist (SNP) was potentiated in eNOS^−/−^ mice, in common with previous observations ([@B13]), thought to be attributed to an increased sensitivity to soluble guanylyl cyclase. Overall these data support previous observations of a reduced vaso-reactivity of UtAs of eNOS^−/−^ mice and a reduced uterine blood flow ([@B37]), although the latter was not measured in this study. The differential effects of PJ on UtAs in the two genotypes may provide clues as to the mechanisms of action of PJ in the uterine vasculature and suggest that, unsurprisingly, differential antioxidant pathways predominate in the absence of the eNOS enzyme.

The structural properties of the phenolic constituents of PJ can mediate scavenging of a number of radicals, including superoxide, hydroxyl groups and peroxy-nitrite, ([@B43]) and (in WT) potentiate NO bioavailability ([@B33]). This can complement endogenous oxidative stress defense mechanisms to improve vascular health ([@B56]; [@B16]), mitigating the damaging effects of these radicals. In the vasculature this has been shown to improve vasodilator responses by preventing the radical mediated oxidation of LDL, which is known to impair endothelium dependent relaxation([@B26]). Polyphenols also augment NO-independent components of vascular relaxation including enhancing Endothelial Derived Hyperpolarizing Factor (EDHF) actions ([@B59]) and stimulating smooth muscle relaxation following voltage-gated ion channel activation ([@B49]), both of which can increase the production of the vasodilator prostacyclin ([@B45]) and decrease production of the constrictor endothelin-1 ([@B25]). Furthermore in WT animals polyphenols interact with eNOS-cGMP signaling ([@B30]; [@B56]) and with antioxidants, increasing eNOS enzyme expression ([@B52]) and NO production ([@B4]).

Despite this wealth of evidence supporting positive effects of pomegranate polyphenols on vascular health, PJ treatment did not beneficially affect vascular function in either WT or eNOS^−/−^ mice in the current study. In eNOS^−/−^ mice, PJ led not to enhanced relaxation but enhanced constriction. Any beneficial effects of PJ on components of vascular reactivity appears insufficient to counteract the deficit in vasodilator effects of NO in the absence of endogenous eNOS in the uterine vasculature of eNOS^−/−^ animals. In WT animals, vessel reactivity to exogenous vasodilators was blunted by PJ treatment in contrast to the positive effects seen in other models, ([@B30]; [@B2]; [@B27]). However, the enhanced constriction to PE observed in UtAs of eNOS^−/−^ mice was absent in arteries from WT mice, again suggesting that the presence of eNOS may provide a protective role above and beyond the actions of PJ.

Effects of Pomegranate Juice in Umbilical Vessels
-------------------------------------------------

It has been demonstrated previously that UmbAs of WT mice do not demonstrate a consistent contractile response to PE ([@B38]) and so the thromboxane mimetic U46619 was used to compare the effect of PJ treatment on UmbA contraction in WT and eNOS^−/−^ mice. Furthermore, UmbAs, in contrast to most arteries including UtAs, contract rather than relax in response to Ach ([@B38]). Agonist induced responses of UmbAs following PJ supplementation were similar between the genotypes suggesting that eNOS and nitric oxide may play a less prominent role in the relaxation of these vessels. Additionally, agonist induced responses were enhanced for all compounds under investigation, both contractile and vasodilatory, either by enhancing sensitivity or maximal responses. Interestingly, although in the majority of vascular beds prostaglandins mediate artery relaxation, in umbilical vessels prostaglandins trigger constriction ([@B1]). This may help explain the increased umbilical artery sensitivity to U46619 following PJ treatment as polyphenols have been demonstrated to increase prostacyclin (PGI~2~) production by endothelial cells in culture ([@B45]). A tendency for UmbAs to constrict may reduce blood flow to the developing fetus, negatively impacting nutrient delivery and fetal growth.

A further consideration is the bioavailability of the polyphenol constituents in PJ and their metabolites not only in the systemic circulation but also the placenta, ([@B58]). Although these data are supportive of dietary polyphenols being present in the placenta and fetal circulation, the milieu of polyphenols present in the fetal circulation is likely to be quite distinct from that in maternal plasma and this could contribute to differences in the effects of PJ on opposing sides of the maternal-fetal interface.

Excessive Polyphenol Consumption May Be Detrimental to Developmental Outcomes
-----------------------------------------------------------------------------

The observed effects on vascular function of both uterine and umbilical vessels were not associated with any improvement in fetal weight in eNOS^−/−^ and there were modest reductions in biometric measurements following PJ supplementation. Polyphenols have previously been shown to negatively affect both fetal development, by causing premature closure of the ductus arteriosus in the third trimester ([@B62]), and nutrient transport processes (reviewed by [@B42]). Interestingly, different polyphenols can have differential effects on nutrient transport. For example, the polyphenols rutin, catechin and quercetin, which are all present in PJ ([@B43]), have been shown to differentially affect glucose transport in placental cells ([@B5]). We were unable to make an assessment of the bioavailability of polyphenols in the present study due to small sample volumes available, a limitation of many preclinical studies. Nevertheless, such alterations in transport could potentially contribute to the growth suppressing effects of PJ supplementation in the current study.

A recently published paper, ([@B22]), examined effect of PJ supplementation in a hypoxic model (12% O~2~ vs. 21% O~2~) of FGR. PJ had no effect on fetal or placental weight in control animals but was able to improve fetal weight under conditions of hypoxia compared to water drinking controls. However, the PJ concentration used was three times that in the present study and the enhancement in fetal weight was in part due to a restoration of calories to these animals; glucose supplementation used to control for energy intake in this study also improved fetal weight.

[@B46] reported that embryo femur length increased following treatment of mice with PJ extract (an in-house prepared PJ extract, administered at 3.3 ml/kg between days 8 and 18 of pregnancy), and that PJ increased cell proliferation and differentiation *in vitro*, consistent with a positive effect of PJ on bone cells. However, a bone growth-promoting effect of PJ (administered from E12.5) was not evident in the current study, as PJ did not affect crown rump length. It is possible that crown-rump length might have increased with extended PJ supplementation; however, the effect of PJ to reduce head circumference and abdominal circumference observed in the current study does not support maternal treatment with PJ over a longer term in our model.

In addition to the lack of improvement in fetal weight in eNOS^−/−^ mice, a striking observation in the present study was a reduction in litter size in both genotypes following PJ supplementation. Interestingly, one of the mechanisms whereby PJ can reduce blood pressure in hypertensive patients is via decreasing angiotensin converting enzyme (ACE) activity ([@B6]). Whist the use of ACE inhibitor drugs are common and are well tolerated in non-pregnant adults, the safety of these drugs in pregnant women has come under question in recent years with other classes of anti-hypertensives being recommended in this patient sub-group ([@B41]). Specifically the use of ACE inhibitors or angiotensin II receptor blockers in pregnancy can lead to low birth weight as well as an increased miscarriage rate compared to untreated pregnant women ([@B47]). This may be a mechanism underpinning the reduction in litter size following PJ supplementation in the current study.

The period of PJ supplementation in the present study can be considered to be roughly equivalent to the second and third trimesters of human pregnancy. The timing of treatment was chosen as it is from the equivalent point in human pregnancy that babies are identified as growth restricted and an intervention could realistically be introduced. However, in the mouse this time also coincides with significant placental growth to E16.5 followed by rapid fetal growth and development ([@B24]). Although beyond the scope of this study, differences in placental function with PJ supplementation during this critical window of development may have adversely effected fetal development as observed in other studies ([@B53]).

Our results indicate that pomegranate supplementation may be detrimental to fetal outcomes in this eNOS^−/−^ mouse model of FGR, which results from of a single gene deletion. Whilst the eNOS^−/−^ model demonstrates many phenotypic similarities to human FGR it is important to note that the etiology of human FGR is complex and our results should be interpreted with caution and investigation in alternative mouse models is warranted before extrapolating the results to pregnant women.

Conclusion
==========

Whilst in other models pomegranate supplementation can have highly beneficial effects on multiple measures of cardiovascular health and vascular function these improvements were not observed in the current study. Indeed, maternal PJ supplementation was associated with a range of detrimental effects on utero-and fetoplacental vascular function, litter size and fetal growth. Although elevated oxidative stress has been implicated in pregnancy complications such as FGR and preeclampsia, artificially altering the anti-oxidant milieu during pregnancy may not always be beneficial ([@B51]). If the effects of PJ on vascular function and fetal well-being observed here were mediated through its actions as an anti-oxidant, our results indicate that upsetting the balance between the generation and sequestration of reactive oxygen species could result in poor pregnancy outcomes. Collectively the data do not support maternal PJ supplementation as a safe or effective treatment for FGR.
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